AU2008223915B2 - Process for the synthesis of GLYT-1 inhibitors - Google Patents
Process for the synthesis of GLYT-1 inhibitors Download PDFInfo
- Publication number
- AU2008223915B2 AU2008223915B2 AU2008223915A AU2008223915A AU2008223915B2 AU 2008223915 B2 AU2008223915 B2 AU 2008223915B2 AU 2008223915 A AU2008223915 A AU 2008223915A AU 2008223915 A AU2008223915 A AU 2008223915A AU 2008223915 B2 AU2008223915 B2 AU 2008223915B2
- Authority
- AU
- Australia
- Prior art keywords
- formula
- compound
- alkyl
- halogen
- room temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07103485 | 2007-03-05 | ||
| EP07103485.4 | 2007-03-05 | ||
| PCT/EP2008/052244 WO2008107334A2 (en) | 2007-03-05 | 2008-02-25 | Process for the synthesis of glyt-1 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2008223915A1 AU2008223915A1 (en) | 2008-09-12 |
| AU2008223915B2 true AU2008223915B2 (en) | 2013-05-02 |
Family
ID=39469606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008223915A Active AU2008223915B2 (en) | 2007-03-05 | 2008-02-25 | Process for the synthesis of GLYT-1 inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7812161B2 (https=) |
| EP (1) | EP2131843B1 (https=) |
| JP (1) | JP4745446B2 (https=) |
| KR (1) | KR101143073B1 (https=) |
| CN (1) | CN101622000B (https=) |
| AT (1) | ATE532516T1 (https=) |
| AU (1) | AU2008223915B2 (https=) |
| BR (1) | BRPI0808570B8 (https=) |
| CA (1) | CA2678630C (https=) |
| ES (1) | ES2375585T3 (https=) |
| IL (1) | IL200323A (https=) |
| MX (1) | MX2009009065A (https=) |
| WO (1) | WO2008107334A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5656474B2 (ja) | 2010-06-28 | 2015-01-21 | 関東化学株式会社 | 脂肪族光学活性フルオロアルコールの製造方法 |
| CN104628679B (zh) * | 2013-11-08 | 2018-02-09 | 江苏恩华药业股份有限公司 | Bitopertin的合成方法及其中间体 |
| CN106397312B (zh) * | 2015-07-31 | 2020-03-24 | 广东东阳光药业有限公司 | 一种制备glyt-1抑制剂的方法 |
| KR20220125326A (ko) | 2020-01-09 | 2022-09-14 | 디스크 메디슨, 인크. | 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법 |
| CA3195702A1 (en) | 2020-10-13 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Process of reworking |
| WO2024042043A1 (en) | 2022-08-24 | 2024-02-29 | Boehringer Ingelheim International Gmbh | A scalable process for the preparation of a glyt-1 inhibitor |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005014563A1 (en) * | 2003-08-11 | 2005-02-17 | F. Hoffmann-La Roche Ag | Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3992441A (en) * | 1972-12-26 | 1976-11-16 | Pfizer Inc. | Sulfamylbenzoic acids |
| US4480102A (en) * | 1982-07-23 | 1984-10-30 | The Dow Chemical Company | 2,3-Difluoro-5-(trifluoromethyl)pyridine and methods of making and using the same |
| DE68912282T2 (de) * | 1988-11-24 | 1994-04-28 | Akzo Nv | 1-[Mono- oder bis(trifluormethyl)-2-pyridinyl]piperazine enthaltende pharmazeutische Zusammensetzungen. |
| DE4235155A1 (de) * | 1992-10-19 | 1994-04-21 | Basf Ag | Verfahren zur Herstellung von Methylsulfonylbenzoesäuren |
| US6384080B1 (en) * | 1998-04-20 | 2002-05-07 | Fujisawa Pharmaceutical Co., Ltd. | Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase |
| DE10112040A1 (de) * | 2001-03-14 | 2002-10-02 | Aventis Pharma Gmbh | Verbessertes Verfahren zur Herstellung von Sulfonylcarboxamidderivaten |
| GB0227240D0 (en) * | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
| HRP20090264T1 (hr) * | 2004-12-09 | 2009-06-30 | F. Hoffmann - La Roche Ag | Derivati fenil-piperazin metanona |
| CA2593453A1 (en) * | 2005-01-06 | 2006-07-13 | F. Hoffmann-La Roche Ag | Sulfanyl substituted phenyl methanones as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| AU2005324024B2 (en) * | 2005-01-07 | 2011-02-17 | F. Hoffmann-La Roche Ag | [4-(Heteroaryl) piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (GlyT-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| CN101218350B (zh) * | 2005-07-08 | 2011-08-31 | 弗·哈夫曼-拉罗切有限公司 | 1,1,1-三氟丙酮的不对称还原反应 |
-
2008
- 2008-02-25 WO PCT/EP2008/052244 patent/WO2008107334A2/en not_active Ceased
- 2008-02-25 AU AU2008223915A patent/AU2008223915B2/en active Active
- 2008-02-25 JP JP2009552166A patent/JP4745446B2/ja active Active
- 2008-02-25 MX MX2009009065A patent/MX2009009065A/es active IP Right Grant
- 2008-02-25 CA CA2678630A patent/CA2678630C/en active Active
- 2008-02-25 ES ES08709206T patent/ES2375585T3/es active Active
- 2008-02-25 BR BRPI0808570A patent/BRPI0808570B8/pt active IP Right Grant
- 2008-02-25 CN CN200880006900XA patent/CN101622000B/zh active Active
- 2008-02-25 AT AT08709206T patent/ATE532516T1/de active
- 2008-02-25 EP EP08709206A patent/EP2131843B1/en active Active
- 2008-02-25 KR KR1020097018418A patent/KR101143073B1/ko active Active
- 2008-02-27 US US12/038,006 patent/US7812161B2/en active Active
-
2009
- 2009-08-10 IL IL200323A patent/IL200323A/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005014563A1 (en) * | 2003-08-11 | 2005-02-17 | F. Hoffmann-La Roche Ag | Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2678630C (en) | 2015-04-14 |
| BRPI0808570B8 (pt) | 2021-05-25 |
| WO2008107334A3 (en) | 2008-10-23 |
| ATE532516T1 (de) | 2011-11-15 |
| MX2009009065A (es) | 2009-08-31 |
| KR20090110368A (ko) | 2009-10-21 |
| BRPI0808570B1 (pt) | 2020-09-15 |
| IL200323A0 (en) | 2010-04-29 |
| US20080221327A1 (en) | 2008-09-11 |
| CN101622000B (zh) | 2012-07-04 |
| JP2010520251A (ja) | 2010-06-10 |
| KR101143073B1 (ko) | 2012-05-08 |
| IL200323A (en) | 2013-11-28 |
| JP4745446B2 (ja) | 2011-08-10 |
| WO2008107334A2 (en) | 2008-09-12 |
| BRPI0808570A2 (pt) | 2014-09-02 |
| EP2131843B1 (en) | 2011-11-09 |
| ES2375585T3 (es) | 2012-03-02 |
| US7812161B2 (en) | 2010-10-12 |
| AU2008223915A1 (en) | 2008-09-12 |
| CN101622000A (zh) | 2010-01-06 |
| CA2678630A1 (en) | 2008-09-12 |
| EP2131843A2 (en) | 2009-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008223915B2 (en) | Process for the synthesis of GLYT-1 inhibitors | |
| WO2006136407A1 (en) | Process for preparing amorphous rosuvastatin calcium free of impurities | |
| CA2810393C (en) | Method of preparing 3-amino-4-(2-oxo-piperidin-1-yl)-butyric acid derivative for synthesizing medicament | |
| ES3014254T3 (en) | Process for the preparation of n-[4-(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide | |
| JP2019147763A (ja) | プロリンアミド化合物の製造方法 | |
| CA2645154C (en) | Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof | |
| CA3175210A1 (en) | Synthesis of a monoacylglycerol lipase inhibitor | |
| CN111233866B (zh) | 托法替尼或其盐的制备方法 | |
| CN115611858A (zh) | 一种全新的尼古丁及其衍生物的制备方法 | |
| WO2023226900A1 (zh) | 2-(哌嗪-2-基)乙腈类衍生物及其制备方法和应用 | |
| JP7536950B2 (ja) | プロリンアミド化合物の製造方法 | |
| CA3161387A1 (en) | Process for the preparation of purine derivatives exhibiting cdk inhibitory activity | |
| JP7279134B2 (ja) | プロリンアミド化合物の製造方法 | |
| KR100743617B1 (ko) | 고광학순도를 갖는 키랄 3-히드록시 피롤리딘 및 그유도체를 제조하는 방법 | |
| KR100868160B1 (ko) | Ｓ-(-)-암로디핀 또는 이의 염의 제조방법 및 이에사용되는 중간체 | |
| JP5397706B2 (ja) | 高純度１−ベンジル−３−アミノピロリジンの製造方法 | |
| CN118146258A (zh) | 一种精草铵膦的制备方法 | |
| EP1634879A1 (en) | Method of selectively introducing amino substituent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |